DE-INCYTE
19.5.2021 23:16:17 CEST | Business Wire | Press release
Incyte (Nasdaq: INCY) today announced that multiple abstracts highlighting data from its oncology portfolio will be presented during the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, held virtually from June 4-8, 2021.
“We look forward to presenting data from across Incyte’s oncology portfolio and partner programs at this year’s ASCO Annual Meeting,” said Steven Stein, M.D., Chief Medical Officer, Incyte. “Data being presented during this congress, including new three-year data from the L-MIND study of tafasitamab in relapsed or refractory diffuse large B-cell lymphoma as well as results of the OPTIC study of ponatinib in chronic phase-chronic myeloid leukemia, underscore our continued focus on advancing science to help meet patients’ needs.”
Key abstracts accepted by ASCO include:
Oral Presentations
Ponatinib
OPTIC Primary Analysis: A Dose-Optimization Study of 3 Starting Doses of Ponatinib (PON)1 (Abstract #7000. Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant.)
Poster Discussions
Tafasitamab
Long-Term Analyses from L-MIND, a Phase 2 Study of Tafasitamab (MOR208) Combined with Lenalidomide (LEN) in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)2 (Abstract #7513. Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia.)
Capmatinib
Capmatinib in MET Exon 14-Mutated, Advanced NSCLC: Updated Results from the GEOMETRY Mono-1 Study3 (Abstract #9020. Session: Lung Cancer—Non-Small Cell Metastatic.)
ePosters
Capmatinib
Capmatinib Efficacy in Patients with NSCLC Identified as METex14 Using an NGS-Based Liquid Biopsy Assay: Results from the GEOMETRY Mono-1 Study3 (Abstract #9111. Session: Lung Cancer—Non-Small Cell Metastatic.)
Patient-Reported Outcomes in Capmatinib-Treated Patients with METex14-Mutated Advanced NSCLC: Results from the Phase 2 GEOMETRY Mono-1 Study3 (Abstract #9056. Session: Lung Cancer—Non-Small Cell Metastatic.)
Phase 1b/2 Study of Capmatinib Plus Gefitinib in Patients with EGFR-Mutated, MET-Dysregulated Non–Small Cell Lung Cancer who Received Prior Therapy: Final Overall Survival and Safety3 (Abstract #9048. Session: Lung Cancer—Non-Small Cell Metastatic.)
Pemigatinib
Pemigatinib for Previously Treated Locally Advanced/Metastatic Cholangiocarcinoma (CCA): Update of FIGHT-202 (Abstract #4086. Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary.)
Retifanlimab
Phase 2 Study of Retifanlimab (INCMGA00012) in Patients (Pts) with Selected Solid Tumors (POD1UM-203) (Abstract #2571. Session: Developmental Therapeutics—Immunotherapy.)
Ruxolitinib-Parsaclisib Combination Studies
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ruxolitinib Plus Parsaclisib in Patients with JAK- and PI3K-Inhibitor Treatment–Naïve Myelofibrosis (Abstract #TPS7058. Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant.)
Tafasitamab
A Phase 3 Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Versus Placebo Plus Lenalidomide and Rituximab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL) (Abstract #TPS7568. Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia.)
First-MIND: A Phase 1b, Open-Label, Randomized Study to Assess Safety of Tafasitamab (tafa) or Tafa + Lenalidomide (LEN) in Addition to R‑CHOP in Patients with Newly Diagnosed DLBCL2 (Abstract #7540. Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia.)
For full session details and data presentation listings, please see the ASCO21 online program at https://meetinglibrary.asco.org . Oral, poster discussion and poster sessions, as well as track-based clinical science symposia, accepted for presentation at ASCO will be available on demand beginning Friday, June 4, 2021 at 9:00 a.m. ET.
About Incyte
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com
and follow @Incyte
.
Forward-Looking Statements
Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the presentation of data from the Company’s or partner company’s ongoing clinical development pipeline, and whether or when any development compounds or combinations will be approved or commercially available for use in humans anywhere in the world outside of the already approved indications in specific regions, its presentation plans for the upcoming ASCO meeting and its goal of improving the lives of patients, contain predictions, estimates and other forward-looking statements.
These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials and the ability to enroll subjects in accordance with planned schedules; the effects of the COVID-19 pandemic and measures to address the pandemic on the Company’s clinical trials, supply chain and other third-party providers, and development and discovery operations; determinations made by the FDA and other regulatory authorities outside of the United States; the Company’s dependence on its relationships with its collaboration partners; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission, including its annual report for the year ended December 31, 2020 and the quarterly report on Form 10-Q for the quarter ended March 31, 2021. The Company disclaims any intent or obligation to update these forward-looking statements.
1
Takeda-sponsored abstract.
2
MorphoSys-sponsored abstract.
3
Novartis-sponsored abstract.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210519005952/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Interactive Brokers Launches Crypto-Asset Trading for Individual Investors in the European Economic Area31.3.2026 11:00:00 CEST | Press release
Eligible clients can now trade 11 popular crypto-assets including Bitcoin and Ethereum alongside stocks, options, futures, and more, all from a single, integrated platform Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of crypto-asset trading for eligible individual investors in the EEA through Interactive Brokers Ireland Limited, which is an authorised crypto-asset service provider in the EEA. Many European investors face challenges managing multiple crypto apps, understanding unclear fees, or navigating security concerns. Interactive Brokers now offers a solution. Starting today, eligible individual investors in the EEA can trade 11 leading crypto-assets directly on the same platform they already use for stocks, options, futures, currencies, bonds, and mutual funds. This integrated approach gives clients a unified view of their entire portfolio. With one login, they can manage both traditional and crypto-assets, backed by the control, low p
Philip Morris International Presents its Value Report 2025: change in motion31.3.2026 10:30:00 CEST | Press release
The company’s annual disclosure unveils its Value Plan 2030+ Philip Morris International (NYSE: PM) today released its Value Report 2025, offering a holistic perspective on the company’s approach to sustainable value creation. The report marks the completion of PMI’s 2025 Roadmap, communicating achievements for each aspiration introduced by the company in 2020, and introduces its Value Plan 2030+, set to guide the company’s continued path to sustainable growth. “For more than a decade, PMI has pursued an industry-leading shift away from cigarettes—a transformation that goes far beyond product innovation to encompass how we allocate capital, engage stakeholders, and measure success,” said Jacek Olczak, Group Chief Executive Officer. “‘change in motion’ captures the reality that transformation is not a project with a defined end date, it is the continuous work of improvement, innovation, and adaptation that keeps us relevant and resilient. We transform continuously because markets evolve
BarmeniaGothaer Modernizes Front-to-Back Investment Platform with Bloomberg and Clearwater Analytics31.3.2026 10:00:00 CEST | Press release
Unified data and a total portfolio view across public and private assets improves transparency, risk oversight, and investment decision-making Bloomberg and Clearwater Analytics (NYSE: CWAN) today announced that BarmeniaGothaer Asset Management AG, one of Germany’s top 10 insurance asset managers managing more than 50 billion euros in assets, has gone live on Bloomberg’s buy-side solutions and has selected Clearwater Analytics as its middle- and back-office management platform, including accounting and data management, completing its front-to-back investment transformation across the organization. The merger of Barmenia and Gothaer in 2024 has created the opportunity to successfully unite two distinct technology and data environments, thereby advancing investment management to a new level. By integrating Bloomberg’s buy-side solutions and Clearwater Analytics into its operations, BarmeniaGothaer Asset Management AG is creating a future-proof investment management workflow that meets th
TREASoURcE Final Conference: 14 April 2026, Brussels – Circular Systemic Solutions: From Demos to Deployment31.3.2026 09:32:00 CEST | Press release
The EU-funded project brings policymakers, industry and cities together to discuss how circular economy solutions can scale beyond pilots. The EU-funded TREASoURcE project will present its key results and policy messages at the Final Conference on 14 April 2026 in Brussels, bringing together policymakers, industry representatives, researchers, cities and civil society actors from across Europe. The full-day conference focuses on how circular economy solutions can move from pilot projects to broader deployment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331360899/en/ Join us in Brussels for the TREASoURcE Final Conference on circular solutions. Over four years, TREASoURcE has developed and tested scalable circular solutions across three value chains: plastics, batteries, and biobased side and waste streams. From demonstrations to deployment: addressing Europe’s scaling challenge The final conference responds to one of
Thermochemical Energy Storage Leader Redoxblox Rebrands as Tempo31.3.2026 09:00:00 CEST | Press release
Breaking the heat barrier: Tempo advances towards commercial rollout of continuously delivered electrified industrial heat at up to 1,200°C Redoxblox, a leader in thermochemical energy storage (TCES) on a mission to electrify the world with technology that shifts the power dynamic, today announced its rebrand to Tempo. The new identity marks the company’s transition from technology development to the commercial scaling of its breakthrough electrified heat platform. The rebrand, developed in partnership with renowned creative agency Red Antler, aligns Tempo’s strategic identity with its unique ability to meet the rigorous demands of heavy industry. The name Tempo is a nod to three core pillars of the company’s value proposition: Temperature leadership, the time-shifting of energy, and the pace of both continuous industrial heat delivery and rapid innovation. “As we move from technical validation toward large-scale commercial rollout, our brand must reflect the scale of the challenge we
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom